Related Experiment Video
Updated: May 22, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues
Hong Liang1, Jie Zhang, Chen Shao
1Department of Respiratory Medicine, Second Affiliated Hospital of Jilin University, Changchun, Jilin 130041, China.
Background:
RNA binding motif 5 (RBM5) is a tumor suppressor gene that modulates apoptosis through the regulation of alternative splicing of apoptosis-related genes. This study aimed to detect RBM5 expression in non-small cell lung cancer (NSCLC) and to associate RBM5 expression with clinicopathological data from NSCLC patients and EGFR and KRAS expression to better understand the potential role of RBM5 in NSCLC.
Method:
Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were performed to detect expression of mRNA and protein, respectively, of RBM5, EGFR and KRAS in 120 paired non-tumor and tumor samples of NSCLC.
Results:
The data showed that expression of RBM5 mRNA and protein was significantly reduced in NSCLC compared to normal tissues, whereas expression of both EGFR and KRAS genes was increased in NSCLC compared to normal tissues. Furthermore, the reduced RBM5 protein expression correlated with smoking status, tumor stage and lymph node metastasis of NSCLC, while overexpression of EGFR and KRAS proteins correlated with tumor stage and lymph node metastasis of NSCLC. Overexpression of KRAS protein was more frequent in smokers with NSCLC. In addition, expression of RBM5 mRNA and protein was negatively correlated with expression of EGFR and KRAS mRNA and protein in NSCLC tissues.
Conclusion:
This study suggests further evaluation of RBM5 expression is warranted for use of RBM5 as a biomarker for NSCLC patients.
Insights
RNA binding motif 5 (RBM5) is reduced in non-small cell lung cancer (NSCLC), correlating with disease progression. RBM5 may serve as a potential biomarker for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Gene Expression Analysis
Background:
- RNA binding motif 5 (RBM5) functions as a tumor suppressor by regulating apoptosis via alternative splicing.
- RBM5 plays a role in cancer development and progression.
Purpose of the Study:
- To investigate RBM5 expression in non-small cell lung cancer (NSCLC).
- To correlate RBM5 expression with clinicopathological features and EGFR/KRAS expression in NSCLC.
- To understand the potential role of RBM5 in NSCLC pathogenesis.
Main Methods:
- Analyzed 120 paired NSCLC and non-tumor tissues.
- Utilized semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) for mRNA detection.
- Employed Western blotting for protein expression analysis of RBM5, EGFR, and KRAS.
Main Results:
- RBM5 mRNA and protein levels were significantly decreased in NSCLC tissues compared to normal tissues.
- EGFR and KRAS gene expression was elevated in NSCLC tissues.
- Reduced RBM5 expression correlated with smoking status, tumor stage, and lymph node metastasis.
- EGFR and KRAS overexpression correlated with tumor stage and lymph node metastasis.
- RBM5 expression showed a negative correlation with EGFR and KRAS expression.
Conclusions:
- RBM5 expression is downregulated in NSCLC.
- RBM5 expression is associated with adverse clinicopathological features in NSCLC.
- RBM5 warrants further investigation as a potential diagnostic or prognostic biomarker for NSCLC.
Related Concept Videos
02:38The Ras Gene
Ras is a superfamily...
01:24Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...